Skip to main content
. 2014 Jul 22;2(3):E162–E175. doi: 10.9778/cmajo.20130073

Table 1: Characteristics of the 14 trials included in the meta-analysis.

Trial Location Design Treatment; no. of patients
Duration of intervention
Sulfonylurea Metformin Total
ADOPT, 20062026
North America, Europe and Canada
Parallel; blinding of investigators and participants
1447
1455
2902
4 yr
Campbell et al., 199427
United Kingdom
Parallel; open label
24
24
48
1 yr
Collier et al., 198928
NR
Parallel; open label
12
12
24
6 mo
DeFronzo et al., 199529
United States
Parallel; blinding of investigators and participants
209
210
419
29 wk
Derosa et al., 200442
Italy
Parallel; open label
81
83
164
12 mo (+ 8-wk titration period)
Hermann et al., 1991a30
Sweden
Crossover; open label
10*
12*
25*
6 mo
Hermann et al., 1991b3134
Sweden
Parallel; blinding of investigators and participants
34
38
72
6 mo + 2–12 wk titration period
Kamel et al., 199735
Turkey
Parallel; blinding of investigators and participants
17†
6
23
24 wk
Lawrence et al., 200436
United Kingdom
Parallel; open label
22
21
43
24 wk
Tang et al., 200441
China
Parallel; open label
33
29
62
6 mo
Tessier et al., 199937
Canada
Parallel; open label
19
20
39
24 wk
Tosi et al., 200338
Italy
Crossover; blinding of investigators and participants
22
22
44
6 mo
UKPDS 34, 19982,39,40
United Kingdom
Parallel; open label
277
342
619
10.7 yr
Yamanouchi et al., 200543 Japan Parallel; NR (we assume open label) 37 39 76 12 mo

Note: ADOPT = A Diabetes Outcome Progression Trial, NR = not reported, UKPDS = United Kingdom Prospective Diabetes Study. 
*Number of participants randomly selected for each intervention arm not reported; only those who completed the trial.
†The 17 participants in the sulfonylurea arm were given either gliclazide (9 participants) or glibenclamide (8 participants).